[SCHEDULE 13G] Aclaris Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 2 to a Schedule 13G for CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS). As of 30 June 2025 Vanguard reports beneficial ownership of 60,251,392 common shares, representing 9.14 % of CCCS’s outstanding stock. Vanguard categorises itself as an investment adviser under Rule 13d-1(b).

Voting authority is minimal: 0 shares with sole voting power and 188,758 shares with shared voting power. Dispositive authority is higher, with 59,447,942 shares subject to sole dispositive power and 803,450 shares subject to shared dispositive power. Vanguard certifies that the holdings are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

The filing indicates that Vanguard’s aggregate position remains passive but confirms that the asset manager continues to hold a stake above the 5 % threshold that triggers Schedule 13G reporting.

Positive

• 9.14 % passive stake by a major index manager underscores institutional confidence and may improve liquidity.

Negative

• None.

Insights

Portfolio Manager

TL;DR – Vanguard owns 9.14 % of CCCS, signalling sizable passive institutional support.

Vanguard’s 60.3 m-share stake provides liquidity and passive index backing for CCCS. While it does not exercise voting control (0 sole votes), the large sole dispositive power means Vanguard can freely trade most of its position, which could influence share supply-demand dynamics. The disclosure is routine but reminds investors that nearly a tenth of the float sits with a price-insensitive holder, potentially dampening volatility yet posing overhang risk if flows reverse. Overall impact neutral-to-mildly positive as continued inclusion in Vanguard index products supports valuation.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aclaris Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00461U105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 37,768.00
7	Sole Dispositive Power 6,578,815.00
8	Shared Dispositive Power 83,248.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,662,063.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.15 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aclaris Therapeutics Inc
(b)	Address of issuer's principal executive offices: 640 Lee Road, Suite 200, Wayne, PA, 19087
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 00461U105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6662063
(b)	Percent of class: 6.15 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 37768
	(iii) Sole power to dispose or to direct the disposition of: 6578815
	(iv) Shared power to dispose or to direct the disposition of: 83248
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How many CCCS shares does Vanguard own?

Vanguard reports 60,251,392 common shares beneficially owned.

What percentage of CCC Intelligent Solutions does Vanguard control?

The filing states 9.14 % of the outstanding class.

Does Vanguard have voting power over its CCCS shares?

It has 0 sole voting power and 188,758 shares of shared voting power.

Why did Vanguard file a Schedule 13G/A?

Its stake exceeds 5 %, requiring disclosure; the amendment updates ownership as of 30 Jun 2025.

Is Vanguard seeking to control CCCS?

No—Vanguard certifies the shares are held in the ordinary course and not to influence control.